Travel Medicine

Resource Center

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

FDA Alerts

FDA Alert
fda
FDA Alert
Tirzepatide Gains FDA Approval for Chronic Weight Management
11/13/2023
Tirzepatide is now approved for a new indication. The dual GIP/GLP-1 agonist was previously approved for treating type 2 diabetes in May 2022.
11/13/2023
FDA Alert
fda
FDA Alert
Tirzepatide Gains FDA Approval for Chronic Weight Management
11/13/2023
Tirzepatide is now approved for a new indication. The dual GIP/GLP-1 agonist was previously approved for treating type 2 diabetes in May 2022.
11/13/2023
fda alert
doctor in white coat
fda alert
FDA Approves Two New Uses of Quizartinib for Acute Myeloid Leukemia
10/19/2023
Leigh Precopio
The FDA approved the use of quizartinib for certain patient populations with acute myeloid leukemia in July 2023.
10/19/2023
fda alert
doctor in white coat
fda alert
FDA Approves Two New Uses of Quizartinib for Acute Myeloid Leukemia
10/19/2023
Leigh Precopio
The FDA approved the use of quizartinib for certain patient populations with acute myeloid leukemia in July 2023.
10/19/2023
fda alert
doctor in white coat
fda alert
FDA Approves Two New Uses of Quizartinib for Acute Myeloid Leukemia
10/19/2023
Leigh Precopio
The FDA approved the use of quizartinib for certain patient populations with acute myeloid leukemia in July 2023.
10/19/2023
FDA Alert
Fda alert
FDA Alert
FDA Approves First Oral Medication for Treatment of Postpartum Depression
10/04/2023
Jessica Ganga
Following two randomized studies, the FDA has approved zuranolone for the treatment of postpartum depression in adults—the first if its kind.
10/04/2023
FDA Alert
Fda alert
FDA Alert
FDA Approves First Oral Medication for Treatment of Postpartum Depression
10/04/2023
Jessica Ganga
Following two randomized studies, the FDA has approved zuranolone for the treatment of postpartum depression in adults—the first if its kind.
10/04/2023
FDA Alert
Fda alert
FDA Alert
FDA Approves First Oral Medication for Treatment of Postpartum Depression
10/04/2023
Jessica Ganga
Following two randomized studies, the FDA has approved zuranolone for the treatment of postpartum depression in adults—the first if its kind.
10/04/2023
FDA Alert
Fda alert
FDA Alert
FDA Approves First Oral Medication for Treatment of Postpartum Depression
10/04/2023
Jessica Ganga
Following two randomized studies, the FDA has approved zuranolone for the treatment of postpartum depression in adults—the first if its kind.
10/04/2023
FDA Alert
Fda alert
FDA Alert
FDA Approves First Oral Medication for Treatment of Postpartum Depression
10/04/2023
Jessica Ganga
Following two randomized studies, the FDA has approved zuranolone for the treatment of postpartum depression in adults—the first if its kind.
10/04/2023